Abstract:IntroductionWith the increasing use of health economic evaluation (HEE) in decision-making and health resource allocation and management policy design has seen an increase in HEE studies on screening programs in China l. In addition to the quantity of HEE, the quality may be of particular concern as it influences the reliability of HEE evidence adopted in policy formulation. This study sought to assess the reporting quality of HEE on screening programs over the last 20 years in China and identify potential predictors and relevant recommendations to improve the quality of study reporting.MethodsA search of HEE studies published in PubMed, Embase, CNKI and WANFANG from 2000 to 2021 was performed. Two reviewers independently extracted data and assessed the quality if reporting using the 24 item Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. The CHEERS score for each study was converted into standardized 0-1 point scale. General liner regression was used to identify predictors associated with the reporting quality.ResultsOne hundred and thirty-three studies met the inclusion criteria. The mean standardized score for the included studies was 0.56 (title), 0.64 (abstract), 0.74 (introduction), 0.58 (methods), 0.40 (results), 0.70 (discussion), and 0.54 (other section). The number and reporting quality of articles published each year showed an overall upward trend. A greater proportion of studies were published in Chinese journal (69.2%), modelling-based (54.9%), conducted by universities/research institutions (45.9%), focused on non-infectious disease (84.2%), using cost-effectiveness analysis method (50.4%), published in non-specialty journal (60.2%), and declaring the funding support (76.7%). Items related to study perspective, discount rate, measurement of effectiveness, currency and price, analytical methods, uncertainty, heterogeneity and conflicts were under-reported. Published year, journal type, first author affiliation and economic evaluation type predicted higher score in regression analyses (p<0.05).ConclusionsOverall, the quantity and quality of HEE on screening programs in China is improving, although there is a need to improve the use of on specific reporting items in the CHEERS criteria. The use of suitable evaluation guidelines will make the decision-making process more scientific.

Methods for Socio-Economic Evaluation of Marketed MedicinesIII: Factors Affecting Methodological Quality and Transferability

Assessment of the quality of pharmacoeconomic evaluation literature in China

Systems analysis and evaluation of Chinese pharmacoeconomic literatures over ifve years

Quality of Pharmacoeconomic Research in China

[Guidelines for Economic Evaluation of Post-Marketing Chinese Patent Medicine].

Evaluation of quality of pharmacoeconomic studies involved in traditional Chinese medicine in China

PD08 A Systematic Review of Reporting Quality of Economic Evaluations in TCM in NRDL of China Based on CHEERS

PD12 Quality Assessment of Health Economic Evaluation on Screening Programs from China

Reporting quality of economic evaluations of the negotiated Traditional Chinese Medicines in national reimbursement drug list of China: A systematic review

Systematic Review and Quality Evaluation of Pharmacoeconomic Studies on Traditional Chinese Medicines

A Critical Review of Chinese Pharmacoeconomics Studies in the Last Five Years.

Evidence-based Research on the Selection Method System for China's Essential Medicine List

Measurement and analysis of equity in health: a case study conducted in Zhejiang Province, China

Were Economic Evaluations Well Reported for the Newly Listed Oncology Drugs in China’s National Reimbursement Drug List

System analysis and evaluation of pharmacoeconomic literatures of cancer published in China

The Quality of Published Health Economic Evaluations on Screening Programs in China: a Systematic Review and Quantitative Appraisal

A Quality Evaluation of Nursing Intervention Studies in Mainland China: from 1979 to 2012

A knowledge-attitude-practice investigation of pharmacoeconomics in different stakeholders

A systematic review of methodology in clinical trial-based health economics study with cost-effectiveness ratio for nutritional drug in T3 transfer of translational medicine

Key Issues of Economic Evaluations for Health Technology Assessment in China: A Nationwide Expert Survey

OP46 Assessing The Quality Of Pharmacoeconomic Evaluations About Type 2 Diabetes Mellitus Drugs In National Reimbursement Drug List